Chen Y, van den Nieuwendijk A, Wu L, Moran E, Skoulikopoulou F, van Riet V
J Am Chem Soc. 2023; 146(1):125-133.
PMID: 38118176
PMC: 10785800.
DOI: 10.1021/jacs.3c04162.
Borlandelli V, Armstrong Z, Nin-Hill A, Codee J, Raich L, Artola M
ChemMedChem. 2022; 18(4):e202200580.
PMID: 36533564
PMC: 10947206.
DOI: 10.1002/cmdc.202200580.
Casto-Boggess L, Holland L, Lawer-Yolar P, Lucas J, Guerrette J
Anal Chem. 2022; 94(46):16151-16159.
PMID: 36343965
PMC: 9686991.
DOI: 10.1021/acs.analchem.2c03584.
Keil J, Rafn G, Turan I, Aljohani M, Sahebjam-Atabaki R, Sun X
J Med Chem. 2022; 65(20):13574-13593.
PMID: 36252951
PMC: 9620260.
DOI: 10.1021/acs.jmedchem.2c01258.
Raihan T, Rabbee M, Roy P, Choudhury S, Baek K, Azad A
Front Mol Biosci. 2021; 8:732256.
PMID: 34557521
PMC: 8452873.
DOI: 10.3389/fmolb.2021.732256.
Synthesis of Pyrrolidine Monocyclic Analogues of Pochonicine and Its Stereoisomers: Pursuit ofSimplified Structures and Potent β--Acetylhexosaminidase Inhibition.
Yan X, Shimadate Y, Kato A, Li Y, Jia Y, Fleet G
Molecules. 2020; 25(7).
PMID: 32218360
PMC: 7180638.
DOI: 10.3390/molecules25071498.
Therapeutic significance of β-glucuronidase activity and its inhibitors: A review.
Awolade P, Cele N, Kerru N, Gummidi L, Oluwakemi E, Singh P
Eur J Med Chem. 2019; 187:111921.
PMID: 31835168
PMC: 7111419.
DOI: 10.1016/j.ejmech.2019.111921.
Streptococcus pneumoniae Sialidase SpNanB-Catalyzed One-Pot Multienzyme (OPME) Synthesis of 2,7-Anhydro-Sialic Acids as Selective Sialidase Inhibitors.
Xiao A, Slack T, Li Y, Shi D, Yu H, Li W
J Org Chem. 2018; 83(18):10798-10804.
PMID: 30105908
PMC: 6327951.
DOI: 10.1021/acs.joc.8b01519.
Novel pH-dependent regulation of human cytosolic sialidase 2 (NEU2) activities by siastatin B and structural prediction of NEU2/siastatin B complex.
Rahman M, Hirokawa T, Tsuji D, Tsukimoto J, Hitaoka S, Yoshida T
Biochem Biophys Rep. 2017; 4:234-242.
PMID: 29124209
PMC: 5669518.
DOI: 10.1016/j.bbrep.2015.09.017.
Microbial metabolites and derivatives targeted at inflammation and bone diseases therapy: chemistry, biological activity and pharmacology.
Adachi H, Nakae K, Sakamoto S, Nosaka C, Atsumi S, Shibuya M
J Antibiot (Tokyo). 2017; .
PMID: 29089599
DOI: 10.1038/ja.2017.138.
Current landscape and future prospects of antiviral drugs derived from microbial products.
Takizawa N, Yamasaki M
J Antibiot (Tokyo). 2017; .
PMID: 29018267
PMC: 7091927.
DOI: 10.1038/ja.2017.115.
Differential effect of various inhibitors on four types of rat sialidase.
Miyagi T, Hata K, Hasegawa A, Aoyagi T
Glycoconj J. 1993; 10(1):45-9.
PMID: 8358226
DOI: 10.1007/BF00731186.
High-throughput microtiter plate-based chromogenic assays for glycosidase inhibitors.
Walker J, Winder J, Kellam S
Appl Biochem Biotechnol. 1993; 38(1-2):141-6.
PMID: 8346902
DOI: 10.1007/BF02916417.
Characterization of myxovirus sialidase.
Aoyagi T, Komiyama T, Nerome K, Takeuchi T, Umezawa H
Experientia. 1975; 31(8):896-8.
PMID: 1157849
DOI: 10.1007/BF02358837.
